J11100: A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer
This research is being done is to compare the effects, good and/or bad, of giving IMGN901 with carboplatin/etoposide chemotherapy followed by IMGN901 alone to giving only carboplatin/etoposide chemotherapy.
Website: http://clinicaltrials.gov/ct2/show/NCT01237678?term=LUNG+IMGN901&rank=1
Prinicipal Investigator: Peter Graze, M.D.
Research Coordinatgor: Venita Alston Crawford, RN (443) 481-4393
J1037: Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy with 5-Azacitidine and Entinostat in Resected Stage I Non-Small Cell Lung Cancer versus Standard Care
The purpose of this study is to demonstrate the effectiveness of two medications; Entinostat and 5-Azacitidine. This research study will compare these medications to Standard of Care Management of their disease. Eligible participants would have undergone surgical resection of stage I Non-Small Cell Lung Cancer.
Link: http://clinicaltrials.gov/ct2/show/study/NCT01207726?term=j1037&rank=1
Principal Investigator: Peter Graze, MD. (410) 753-5300
Research Staff: Steven DeMartino, CCRC, CRT, RPFT, AEC (410) 481-4390
Carol Bell, RN (410) 481- 4393
MO22097: An Open-Label, Randomized, Phase IIIb Trial Evaluating The Efficacy And Safety Of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression Of Disease In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment With Bevacizumab Plus A Platinum Doublet-Containing Chemotherapy.
Standard of care for patients with locally advanced or metastatic Non-Small Cell Lung Cancer is platinum-based doublet chemotherapy. Double-agent chemotherapy has been found to be superior to single-agent chemotherapy, with Cisplatin-based treatment being the current reference treatment for patients with advanced Non-Small Cell Lung Cancer. However, no combination has been proven to be clinically superior to the others. Recent trials have shown that patients with advanced NSCLC can benefit from 2nd-line treatment. Currently, Docetaxel and Pemetrexed are two widely used chemotherapy agents approved for use as 2nd-line treatment. This clinical trial would continue Bevacizumab along with the presently used chemotherapy agent in 2nd line treatment.
Link: http://clinicaltrials.gov/ct2/show/study/NCT01351415?term=mo22097&rank=1&show_locs=Y#locn
Principal Investigator: Peter Graze, MD. (410) 753-5300
Research Staff: Steven DeMartino, CCRC, CRT, RPFT, AEC (410) 481-4390
Elizabeth Egan, RN (410) 481-5811
Rapid Chest and Lung Assessment Program Screening Trial
This protocol will offer enrollment to current or former heavy smokers concerned about their health and would like to be screened for possible effects of long-term tobacco use. The study will include screening, follow-up and the opportunity to enroll in a smoking cessation program to help reduce the incidence or reoccurrence of lung cancer.
Principal Investigator: Dr. Peter Graze – (410)573-5300
Research Coordinator: Steven DeMartino, CCRC, CRT, RPFT, AEC - (443)481-4390
MAGRIT: A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of reMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGEA3-positive Non-Small Cell Lung Cancer
The purpose of this study is to demonstrate the clinical efficacy of recMAGE-A3 + AS15 versus placebo. This study will compare the efficacy in the overall population and the efficacy in the population of patients who did not receive adjuvant chemotherapy. This research study is for patients with resectable MAGEA3-positive non-small cell lung cancer.
Website: http://clinicaltrials.gov/ct2/results?term=MAGRIT
Principal Investigator: Dr. Peter Graze – (410)573-5300
Research Coordinator: Emily Ross, CCRC – (443)481-4392
OAM4971g: A randomized, Phase III, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (MetMAb) in combination with Tarcevaâ (Erlotinib) in patients with met diagnostic-positive non-small cell lung cancer (NSCLC) who have received standard chemotherapy for advanced or metastatic disease
This is a study of an investigational agent called MetMAb, to be used in combination with erlotinib (Tarceva), an approved therapy for patients with non-small cell lung cancer. The cancer therapy used in this study is erlotinib, a drug that has been approved by the FDA and other health authorities for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy regimen.
http://clinicaltrials.gov/ct2/show/NCT01456325?term=cell+lung+cancer+AND+maryland+AND+metmab&rank=1�
Principal Investigator: Dr. Peter Graze, MD. (443) -573-5300
Research Staff: Emily Ross, CCRC (443)-481-4392
Steven DeMartino, CCRC, CRT, RPFT, AEC(443) -481-4390
ASAP: Impact of Aggressive versus Standard Drainage Regimen Using a Long-Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients with Malignant Pleural Effusions �
The study purpose is to compare the incidence of auto-pleurodesis utilizing aggressive drainage versus standard drainage regimens with the PleurRx® catheter. Eligible participants will have pleural effusion and are undergoing the placement of the PleuRx® catheter. Enrolled participants will be randomly assigned to either an aggressive drainage regimen or the standard drainage regimen and will be regularly followed for up to 12 weeks after the placement of the PleuRx® catheter.
http://clinicaltrials.gov/ct2/show/NCT00978939?term=MALIGNANT+PLEURAL+EFFUSION+MARYLAND&rank=2�
Principal Investigator: Dr. Stephen Cattaneo, MD. (443)- 481-3366
Research Staff: Elizabeth Egan, RN (443)- 481-5811